CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Dextromethorphan +1 moredrug
Likely dose
Dextromethorphan 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03538054
NCT03538054Phase 2Completed
CompareCT.gov

Dextromethorphan in Fibromyalgia

University of Alabama at Birmingham·interventional·Posted May 25, 2018·Updated Aug 26, 2022

In Brief

A Phase 2 clinical trial evaluating Dextromethorphan and Placebo for Fibromyalgia. Completed, enrolled 27 participants across 1 site.

Detailed Summary

The objective of this protocol is to evaluate if Dextromethorphan (DXM) reduces Fibromyalgia (FM) pain. DXM is a drug found in several over-the-counter products, including cough suppressants. The drug may reduce FM pain by suppressing inflammation in the central nervous system. The investigators will be observing the effects of DXM on daily self-reported pain measures in people with FM. If DXM reduces FM pain, it will provide important information about the nature of FM pathophysiology.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 25, 2018
Enrollment StartJun 26, 2018
Primary CompletionMar 18, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.1 years ago

Interventions

Dextromethorphandrug

(1)10 mg, by mouth, twice daily every 12 hours.

Placebodrug

1 capsule, by mouth, twice daily every 12 hours.